Compare Monster Beverage Corp (MNST) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Monster Beverage Corp vs Novartis AG — how do they compare? Monster Beverage Corp trades at $43.64 (market cap $85.51B), while Novartis AG trades at $143.75 (market cap $268.57B). The key difference: Novartis AG is far larger — about 3.1× Monster Beverage Corp's market cap, and Novartis AG pays a 3.31% dividend while Monster Beverage Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Monster Beverage Corp for 72 Days and Novartis AG for 82 Days on average.
| MNST | NVS | |
|---|---|---|
Market Cap | $85.51B | $268.57B |
Volume | 8,569,709 | 1,532,573 |
Sector | Consumer Staples | Health |
52-Week High | $49.97 | $168.62 |
52-Week Low | $33.16 | $121.80 |
Typical Hold Time | 72 Days | 82 Days |
Enterprise Value | $83.81B | $309.89B |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Monster Beverage (MNST) trades at $43.65, up 1.8% with bullish technical signals and strong fundamentals. The stock shows consistent earnings beats with Q2 2026 EPS of $0.30 exceeding expectations. Revenue grew to $8.29B in 2025 with impressive 23.08% net margins and zero long-term debt. Recent 1:2 stock split on August 11, 2026, enhances accessibility while international sales surge 35% in Q2 2026.
MNST presents growth potential through international expansion and clean balance sheet, but faces valuation concerns with P/E of 40.42. Analyst consensus targets $98.22 (52% buy ratings) suggesting significant upside. Key risks include regulatory challenges in markets like India and competitive pressure from beverage giants. The stock's premium valuation requires sustained high growth to justify current levels.
Novartis (NVS) trades at $143.11, down 0.12% with a bearish technical signal. The stock shows strong fundamentals with 24.67% net margin and $14B net income, though recent earnings were mixed with a Q1 miss. Analyst consensus is cautious with 68% hold ratings and a $146 target. Recent $7.8B licensing deal with China's Abogen highlights strategic moves amid pipeline setbacks.
Outlook remains balanced: valuation metrics appear reasonable (P/E 21.6) and profitability is robust, but clinical trial failures and investor scrutiny over M&A strategy pose risks. The stock trades near consensus target with institutional sentiment leaning neutral amid ongoing pipeline execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Monster Beverage Corp
Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
